Brooks Jackson

Dr. Brooks Jackson

orcid

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 1999 in The Lancet
Verified
Journal Article
Open access
LGLaura A Guay
Laura A Guay
PMPhilippa Musoke
Philippa Musoke
TFThomas Fleming
Thomas Fleming
DBDanstan Bagenda
Danstan Bagenda
MAMelissa Allen
Melissa Allen
BJBrooks Jackson
Brooks Jackson
The AIDS Clinical Trials Group protocol 076 zidovudine prophylaxis regimen for HIV-1-infected pregnant women and their babies has been associated with a significant decrease in vertical HIV-1 transmission in non-breastfeeding women in developed countries. We compared the safety and efficacy of short-course nevirapine or zidovudine during labour and the first week of life. From November, 1997, to April, 1999, we enrolled 626 HIV-1-infected pregnant women at Mulago Hospital in Kampala, Uganda. We randomly assigned mothers nevirapine 200 mg orally at onset of labour and 2 mg/kg to babies within 72 h of birth, or zidovudine 600 mg orally to the mother at onset of labour and 300 mg every 3 h until delivery, and 4 mg/kg orally twice daily to babies for 7 days after birth. We tested babies for HIV-1 infection at birth, 6-8 weeks, and 14-16 weeks by HIV-1 RNA PCR. We assessed HIV-1 transmission and HIV-1-free survival with Kaplan-Meier analysis. Nearly all babies (98.8%) were breastfed, and 95.6% were still breastfeeding at age 14-16 weeks. The estimated risks of HIV-1 transmission in the zidovudine and nevirapine groups were: 10.4% and 8.2% at birth (p=0.354); 21.3% and 11.9% by age 6-8 weeks (p=0.0027); and 25.1% and 13.1% by age 14-16 weeks (p=0.0006). The efficacy of nevirapine compared with zidovudine was 47% (95% CI 20-64) up to age 14-16 weeks. The two regimens were well tolerated and adverse events were similar in the two groups. Nevirapine lowered the risk of HIV-1 transmission during the first 14-16 weeks of life by nearly 50% in a breastfeeding population. This simple and inexpensive regimen could decrease mother-to-child HIV-1 transmission in less-developed countries.

5 August 1999 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
PGPatricia M. Garcia
Patricia M. Garcia
LKLeslie A. Kalish
Leslie A. Kalish
JPJane Pitt
Jane Pitt
HMHoward Minkoff
Howard Minkoff
TQThomas C. Quinn
Thomas C. Quinn
JLJudy F. Lew
Judy F. Lew
The importance of plasma levels of human immunodeficiency virus type 1 (HIV-1) RNA in pregnant women in relation to the other factors known to influence the risk of transmission of infection to their infants is incompletely defined. We studied the relation of maternal plasma HIV-1 RNA levels to the risk of perinatal transmission and the timing of transmission.

1 September 2003 in The Lancet
Verified
Journal Article
Closed access
BJBrooks Jackson
Brooks Jackson
PMPhilippa Musoke
Philippa Musoke
TFThomas Fleming
Thomas Fleming
LGLaura A Guay
Laura A Guay
DBDanstan Bagenda
Danstan Bagenda
FMFrancis Mmiro
Francis Mmiro

10 October 1996 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
DKDavid A. Katzenstein
David A. Katzenstein
SHScott M. Hammer
Scott M. Hammer
MHMichael D. Hughes
Michael D. Hughes
HGHolly Gundacker
Holly Gundacker
BJBrooks Jackson
Brooks Jackson
MHMartin S. Hirsch
Martin S. Hirsch
We studied measures of human immunodeficiency virus (HIV) replication, the viral phenotype, and immune function (CD4 cell counts) and the relation of changes in these indicators to clinical outcomes in a subgroup of patients in a controlled trial of early antiretroviral treatment for HIV, the AIDS Clinical Trials Group Study 175.

16 February 2005 in JAMA
Verified
Journal Article
Open access
PDF file
RNRichard E. Nettles
Richard E. Nettles
TKTara L. Kieffer
Tara L. Kieffer
PKPatty Kwon
Patty Kwon
DMDaphne Monie
Daphne Monie
YHYefei Han
Yefei Han
RSRobert F. Siliciano
Robert F. Siliciano
Treatment of human immunodeficiency virus type 1 (HIV-1) infection with highly active antiretroviral therapy (HAART) can suppress viremia to below the limit of detection of available clinical assays.1-3 The current goal of antiretroviral therapy is suppression of viremia to below 50 copies/mL of HIV-1 RNA, the limit of detection of the most sensitive available clinical assay.4,5 Suppression to this level is necessary to prevent drug resistance, the major cause of treatment failure.6,7 After achieving suppression, many patients experience intermittent episodes of detectable viremia (“blips”).8-16 Blips may raise concern that resistance is developing and complicate management by increasing patient anxiety, triggering costly repeat measurements of viral load, and generating uncertainty regarding whether therapy should be altered.

22 May 1997 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
JJJeffrey M. Jacobson
Jeffrey M. Jacobson
JGJohn S. Greenspan
John S. Greenspan
JSJohn Spritzler
John Spritzler
NKNzeera Ketter
Nzeera Ketter
JFJohn L. Fahey
John L. Fahey
DWDavid A. Wohl
David A. Wohl
In patients with advanced human immunodeficiency virus (HIV) infection, aphthous ulceration of the mouth and oropharynx can become extensive and debilitating. Preliminary reports suggest that thalidomide may promote the healing of oral aphthous ulcers. We performed a double-blind, randomized, placebo-controlled study of thalidomide as therapy for oral aphthous ulcers in HIV-infected patients. The patients received a four-week course of either 200 mg of thalidomide or placebo orally once per day. They were evaluated weekly for the condition of the ulcers, their quality of life, and evidence of toxicity. Assays were performed for plasma tumor necrosis factor α (TNF-α), soluble TNF-α receptors, and HIV RNA. Sixteen of 29 patients in the thalidomide group (55 percent) had complete healing of their aphthous ulcers after four weeks, as compared with only 2 of 28 patients in the placebo group (7 percent; odds ratio, 15; 95 percent confidence interval after adjustment for group sequential testing, 1.8 to 499; unadjusted P<0.001). Pain diminished and the ability to eat improved with thalidomide treatment. The adverse effects noted with thalidomide included somnolence and rash (7 patients each), and 6 of the 29 patients discontinued treatment because of toxicity. Thalidomide treatment increased HIV RNA levels (median increase, 0.42 log10 copies per milliliter; increase with placebo, 0.05; P = 0.04). With thalidomide treatment there were unexpected increases in the plasma concentrations of TNF-α and soluble TNF-α receptors. Thalidomide is an effective treatment for aphthous ulceration of the mouth and oropharynx in patients with HIV infection.